BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 16135638)

  • 1. Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine.
    Graham KA; Gu H; Lieberman JA; Harp JB; Perkins DO
    Am J Psychiatry; 2005 Sep; 162(9):1744-6. PubMed ID: 16135638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study.
    Wu RR; Zhao JP; Guo XF; He YQ; Fang MS; Guo WB; Chen JD; Li LH
    Am J Psychiatry; 2008 Mar; 165(3):352-8. PubMed ID: 18245179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain.
    Henderson DC; Copeland PM; Daley TB; Borba CP; Cather C; Nguyen DD; Louie PM; Evins AE; Freudenreich O; Hayden D; Goff DC
    Am J Psychiatry; 2005 May; 162(5):954-62. PubMed ID: 15863798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amantadine for weight gain associated with olanzapine treatment.
    Deberdt W; Winokur A; Cavazzoni PA; Trzaskoma QN; Carlson CD; Bymaster FP; Wiener K; Floris M; Breier A
    Eur Neuropsychopharmacol; 2005 Jan; 15(1):13-21. PubMed ID: 15572269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.
    McQuade RD; Stock E; Marcus R; Jody D; Gharbia NA; Vanveggel S; Archibald D; Carson WH
    J Clin Psychiatry; 2004; 65 Suppl 18():47-56. PubMed ID: 15600384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Open label study of the effect of amantadine on weight gain induced by olanzapine.
    Bahk WM; Lee KU; Chae JH; Pae CU; Jun T; Kim KS
    Psychiatry Clin Neurosci; 2004 Apr; 58(2):163-7. PubMed ID: 15009821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weight gain management in patients with schizophrenia during treatment with olanzapine in association with nizatidine.
    Assunção SS; Ruschel SI; Rosa Lde C; Campos JA; Alves MJ; Bracco OL; de Lima MS
    Braz J Psychiatry; 2006 Dec; 28(4):270-6. PubMed ID: 17242805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study.
    Poyurovsky M; Isaacs I; Fuchs C; Schneidman M; Faragian S; Weizman R; Weizman A
    Am J Psychiatry; 2003 Feb; 160(2):297-302. PubMed ID: 12562576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study.
    Baptista T; Uzcátegui E; Rangel N; El Fakih Y; Galeazzi T; Beaulieu S; de Baptista EA
    Psychiatry Res; 2008 May; 159(1-2):250-3. PubMed ID: 18374423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Olanzapine versus placebo in the treatment of adolescents with bipolar mania.
    Tohen M; Kryzhanovskaya L; Carlson G; Delbello M; Wozniak J; Kowatch R; Wagner K; Findling R; Lin D; Robertson-Plouch C; Xu W; Dittmann RW; Biederman J
    Am J Psychiatry; 2007 Oct; 164(10):1547-56. PubMed ID: 17898346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial.
    Baptista T; Martínez J; Lacruz A; Rangel N; Beaulieu S; Serrano A; Arapé Y; Martinez M; de Mendoza S; Teneud L; Hernández L
    Can J Psychiatry; 2006 Mar; 51(3):192-6. PubMed ID: 16618011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial.
    Narula PK; Rehan HS; Unni KE; Gupta N
    Schizophr Res; 2010 May; 118(1-3):218-23. PubMed ID: 20207521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis.
    McGlashan TH; Zipursky RB; Perkins D; Addington J; Miller T; Woods SW; Hawkins KA; Hoffman RE; Preda A; Epstein I; Addington D; Lindborg S; Trzaskoma Q; Tohen M; Breier A
    Am J Psychiatry; 2006 May; 163(5):790-9. PubMed ID: 16648318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
    Simpson GM; Glick ID; Weiden PJ; Romano SJ; Siu CO
    Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Placebo-controlled trial of atomoxetine for weight reduction in people with schizophrenia treated with clozapine or olanzapine.
    Ball MP; Warren KR; Feldman S; McMahon RP; Kelly DL; Buchanan RW
    Clin Schizophr Relat Psychoses; 2011 Apr; 5(1):17-25. PubMed ID: 21459735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia.
    Ascher-Svanum H; Stensland M; Zhao Z; Kinon BJ
    BMC Psychiatry; 2005 Jan; 5():3. PubMed ID: 15649317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.
    Kinon BJ; Basson BR; Gilmore JA; Tollefson GD
    J Clin Psychiatry; 2001 Feb; 62(2):92-100. PubMed ID: 11247108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study.
    Poyurovsky M; Tal V; Maayan R; Gil-Ad I; Fuchs C; Weizman A
    Eur Neuropsychopharmacol; 2004 Aug; 14(4):332-6. PubMed ID: 15163444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of treatment algorithms including amantadine, metformin, and zonisamide for the prevention of weight gain with olanzapine: a randomized controlled open-label study.
    Hoffmann VP; Case M; Jacobson JG
    J Clin Psychiatry; 2012 Feb; 73(2):216-23. PubMed ID: 21672497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma nitric oxide and leptin values in patients with olanzapine-induced weight gain.
    Atmaca M; Tezcan E; Ustundag B
    J Psychiatr Res; 2007; 41(1-2):74-9. PubMed ID: 16426639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.